Centchroman vs tamoxifen for regression of XXXX : A randomized controlled trial.

@entity1 @entity5026 @entity1866 @entity42 @entity158
INTRODUCTION: Several agents have been tried in the management of @entity5026 . Centchroman (Ormeloxifene), a novel non-steroidal selective estrogen receptor modulator (SERM), has also been recently used in the management of @entity5026 . METHODS: Eligible @entity1 , who had @entity5026 for more than 3 months, were randomized into two groups - Group A received centchroman 30  mg daily and Group B received tamoxifen 10  mg daily. Treatment was continued for a total of 12 weeks; thereafter, @entity1 were followed for another 12 weeks without medication to assess the continuum of relief. @entity158 severity was measured with VAS score. @entity1 were considered to have complete @entity158 relief if their VAS score decreased to 3 or less. RESULTS: @entity1 , in both the groups, showed gradual improvement in @entity5026 with passage of time up to 12 weeks. Following cessation of treatment at 12 weeks, partial relapse of @entity158 was observed at 24 weeks. There was no significant difference between Group A and Group B in terms of mean VAS Score and proportion of @entity1 reporting @entity158 relief at 4, 8, 12, and 24 weeks. Fifteen @entity1 in Group A had side effects namely dizziness, @entity1866 and development of @entity42 . There was no side effect noted in group B. CONCLUSION: Centchroman and tamoxifen were found to be of similar effectiveness in providing @entity158 relief in @entity5026 . High frequency of side effects, particularly development of @entity42 , in @entity1 receiving centchroman is a matter of concern.
